We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.46 | -1.50% | 95.81 | 97.83 | 97.11 | 97.63 | 1,180,808 | 00:15:40 |
By Neil MacLucas
ZURICH-Novartis AG (NVS) Thursday said it will begin selling the first biosimilar drug in the U.S. after an appeals court in Washington rejected a request to block the Swiss drug maker's sale of its copycat version of Amgen Inc.'s blockbuster remedy, Neupogen.
Basel-based Novartis's move followed the decision Wednesday by the U.S. Court of Appeals for the Federal Circuit which has cleared the way for the firm's Sandoz unit to start selling Zarxio, a knockoff version of Neupogen that was approved by the U.S. Food and Drug Administration in March. The U.S. market accounted for more than 70% of Amgen's $1.16 billion in global sales of Neupogen last year, a drug for treating chemotherapy patients.
Zarxio was the first biosimilar--a copy of a biotechnology drug--approved by the FDA under abbreviated criteria enabled by a provision of the 2010 Affordable Care Act. However the product's introduction has been delayed by a legal dispute between Amgen and Novartis.
Novartis hasn't announced a price for Zarxio. In Europe, where biosimilars have been available for several years, they typically cost 15% to 30% less than the original brands.
Write to Neil MacLucas at neil.maclucas@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 03, 2015 02:34 ET (06:34 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions